Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium

European Journal of Pharmacology

Volumn 321, Issue 2, 1997, Pages 201-208

  Miao, Lin ^a   Perreault, Cynthia L ^a   Travers, Kerry E ^a   Morgan, James P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Ca2+, intracellular; cAMP; Heart failure; Na+ Ca2+ exchange

Indexed keywords

AMILORIDE; CADMIUM; CHOLINE; FLOSEQUINAN; HYDRALAZINE; MILRINONE; OUABAIN; PROCAINE; TETRODOTOXIN; VERAPAMIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FERRET; HEART PAPILLARY MUSCLE; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; SODIUM CALCIUM EXCHANGE;

AEQUORIN; ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CARRIER PROTEINS; ENZYME INHIBITORS; FERRETS; HEART; HYDRALAZINE; MALE; MILRINONE; MYOCARDIAL CONTRACTION; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; PROCAINE; PYRIDONES; QUINOLINES; SODIUM-CALCIUM EXCHANGER; SODIUM-HYDROGEN ANTIPORTER; STIMULATION, CHEMICAL; TETRODOTOXIN; VASODILATOR AGENTS; VERAPAMIL;

EID: 0031050814     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00946-6     Document Type: Article

References (49)

1. Alousi, A.A. and D.C. Johnson, 1986, Pharmacology of the bipyridines: amrinone and milrinone, Circulation 73, III10.
2. Azuma, J., A. Sawamura, H. Harada, N. Awata, S. Kishimoto and N. Sperelakis, 1987, Mechanism of direct cardiostimulating actions of hydralazine, Eur. J. Pharmacol. 135, 137.
3. Benotti, J.R., L.J. Lesko, J.E. McCue and J.S. Alpert, 1985, Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure, Am. J. Cardiol. 1, 685.
4. Binkley, P.F., E. Nunziata and R.J. Cody, 1994, Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanisms of the positive chronotrope effect and survival influence of long-term vasodilator administration, Am. Heart J. 128, 1147.
5. Blinks, J.R., 1966, Field stimulation as a means of effecting the graded release of autonomic transmitters in isolated heart muscle, J. Pharmacol. Exp. Ther. 151, 221.
6. 2+ indicator in cellular physiology, in: Techniques in Cellular Physiology, ed. P.F. Baker (Elsevier, Amsterdam) p. 1.
7. Bohm, M., F. Diet, G. Feiler, B. Kemkes, E. Kreuzer, C. Weinhold and E. Erdmann, 1988, Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation, J. Cardiovasc. Pharmacol. 12, 726.
8. Cohn, J.N., 1991, Future directions in vasodilator therapy for heart failure, Am. Heart J. 121, 969.
9. Cohn, J.N., D.G. Archibald and S. Ziesche, 1986, Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of Veterans Administration Cooperative Study, New Engl. J. Med. 314, 1547.
10. Cohn, J.N., M.S. Johnson and S. Ziesche, 1991, A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure, New Engl. J. Med. 325, 303.
11. Colucci, W.S., 1991, Cardiovascular effects of milrinone, Am. Heart J. 121, 1945.
12. Corin, W.J., E.S. Monrad, J.A. Strom, S. Giustino, E.S. Sonnenblick and T. LeJemtel, 1991, Flosequinan: a vasodilator with positive inotropic activity, Am. Heart J. 121, 537.
13. Cowley, A.J., 1991, Clinical efficacy of flosequinan in heart failure, Am. Heart J. 121, 983.
14. Earl, C.Q., J. Linden and W.B. Weglicki, 1986, Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone, J. Cardiovasc. Pharmacol. 8, 864.
15. Eid, H., M. O'Neill, B. Kraemer, M. Reus, R. Kelly and T.W. Smith, 1989, Endothelin: a potent positive inotrope in isolated rat ventricular myocytes, Circulation 80 (Suppl. 2), II-193.
16. Elborn, J.S., C.F. Stanford and D.P. Nicholls, 1989, Effect of flosequinan on exercise capacity and symptoms in severe heart failure, Br. Heart J. 61, 331.
17. Feldman, M.D., L. Copelas, J.K. Gwathmey, P. Phillips, E. Warren, F.J. Schoen, W. Grossman and J.P. Morgan, 1987, Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure, Circulation 75, 331.
18. Frodsham, G. and R.B. Jones, 1992, Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle, Eur. J. Pharmacol. 211, 383.
19. 2+ in cardiac myocytes, Circ. Res. 71, 870.
20. Greenberg, S. and B. Touhey, 1990, Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog, J. Cardiovasc. Pharmacol. 15, 900.
21. Gwathmey, J.K. and J.P. Morgan, 1985, The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret, Br. J. Pharmacol. 85, 97.
22. Ishii, A., K. Kubo, T. Deguchi and M. Tanaka, 1979, Inhibition of cyclic AMP phosphodiesterase activity by ecarazine, hydrochloride, hydralazine and their metabolites, Yakagaku Zasshi 99, 533.
23. Jacobs, M., 1984, Mechanism of action of hydralazine on vascular smooth muscle, Biochem. Pharmacol. 33, 2915.
24. Kaczorowski, G., R.S. Slaughter, V.F. King and M.L. Garcia, 1989, Inhibitors of sodium-calcium exchange: identification and development of probes of transport activity, Biochim. Biophys. Acta 988, 287.
25. Katz, A.M., 1983, Cyclic adenosine monophosphate effects on the myocardium: a man who blows hot and cold with one breath, J. Am. Coll. Cardiol. 2, 143.
26. Kihara, Y. and J.P. Morgan, 1989, A comparative study of three methods for intracellular loading of the calcium indicator aequorin in ferret papillary muscles, Biochem. Biophys. Res. Commun. 162, 402.
27. Kreye, V.A.W., 1984, Direct vasodilators with unknown modes of action: the nitro-compounds and hydralazine, J. Cardiovasc. Pharmacol. 6, S646.
28. Kruszyna, H., R. Kruszyna, R.P. Smith and D.E. Wilcox, 1987, Red blood cells generate nitric oxide from directly acting, nitrogenous vasodilators, Toxicol. Appl. Pharmacol. 91, 429.
29. Leier, C.V., C.E. Desch, R.D. Magorien, D.W. Triffon, D.V. Unverferth, H. Boudoulas and R.P. Lewis, 1980, Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting of congestive heart failure, Am. J. Cardiol. 46, 1039.
30. Ludmer, P.L., R.F. Wright, J.M. Arnold, P. Ganz, E. Braunwald and W.S. Colucci, 1986, Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique, Circulation 73, 130.
31. MacKinnon, R., J.K. Gwathmey, P.D. Allen, G.M. Briggs and J.P. Morgan, 1988, Modulation by the thyroid state of intracellular calcium and contractility in ferret ventricular muscle, Circ. Res. 63, 1080.
32. Miao, L., D. Hurrell, C.L. Perreault and J.P. Morgan, 1992, Cyclic AMP-independent inotropic action of flosequinan, Circulation 86 (Suppl. 1), I-622.
33. Morgan, J.P., 1991, Mechanisms of disease: abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction, New Engl. J. Med. 325, 625.
34. Morgan, J.P., J.K. Gwathmey, T.T. DeFeo and K.G. Morgan, 1986, The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle, Circulation 73, III-65.
35. 23Na-nuclear magnetic resonance study of the isolated rat heart, Circulation 86, 302.
36. Opie, L., 1986, Inodilators, Lancet i, 1336.
37. Packer, M., J.R. Carver, R.J. Rodeheffer, R.J. Ivanhoe, R. DiBianco, S.M. Zeldis, G.H. Hendrix, W.J. Bommer, U. Elkayam and M.L. Kukin, 1991, Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group, New Engl. J. Med. 325, 1468.
38. 2+ responsiveness of ferret ventricular myocardium, Br. J. Pharmacol. 101, 679.
39. Perreault, C.L., N.L. Hague, E. Loh, I.M. Hunneyball, M.F. Sim and J.P. Morgan, 1992, Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure, Br. J. Pharmacol. 106, 511.
40. Philipson, K.D., 1985, Sodium-calcium exchange in plasma membrane vesicles, Annu. Rev. Physiol. 47, 561.
41. Resnick, M.S., L.A. Maitland and K.G. Morgan, 1991, Flosequinan, a vasodilator with a novel mechanism of action, Br. J. Pharmacol. 102, 974.
42. Rudd, P. and T.F. Blaschke, 1985, Antihypertensive agents and drug therapy of hypertension, in: Goodman and Gilman's The Pharmacological Basis of Therapeutics, eds. A.G. Gilman, T.W. Rall, A.S. Nies and P. Taylor (Pergamon Press, New York, NY) p. 784.
43. Saegusa, K., Y. Furukawa and S. Chiba, 1986, Pharmacological analyses of hydralazine-induced cardiac action in intact dogs and isolated, blood-perfused canine atria, J. Cardiovasc. Pharmacol. 8, 614.
44. Sheu, S.D. and M.P. Blaustein, 1991, Sodium/calcium exchange and control of cell calcium and contractility in cardiac and vascular smooth muscles, in: The Heart and Cardiovascular System, eds. H.A. Fozzard, E. Haber, R.B. Jennings, A.M. Katz and H.E. Morgan (Raven Press, New York, NY) p. 903.
45. Siegl, P.K.S., E.J. Cargoe Jr., M.J. Trumble and J. Kaczorowski, 1984, Inhibition of Na-Ca exchange in membrane vesicle and papillary preparations from guinea pig heart by analogs of amiloride, Proc. Natl. Acad. Sci. USA 81, 3238.
46. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone, J. Pharmacol. Exp. Ther. 247, 34.
47. Spokas, E.G., G. Folco, J. Quilley, P. Chamdee and J.C. McGif, 1983, Endothelial mechanism in the vascular action of hydralazine, Hypertension 5, I107.
48. 2+ in cardiac myocytes, Am. J. Physiol. 261, H1671.
49. Yates, D.B., 1991, Pharmacology of flosequinan, Am. Heart J. 121, 974.